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Abstract
Background: Variation at the PPARG locus may influence susceptibility to type 2 diabetes and
related traits. The Pro12Ala polymorphism may modulate receptor activity and is associated with
protection from type 2 diabetes. However, there have been inconsistent reports of its association
with obesity. The silent C1431T polymorphism has not been as extensively studied, but the rare T
allele has also been inconsistently linked to increases in weight. Both rare alleles are in linkage
disequilibrium and the independent associations of these two polymorphisms have not been
addressed.
Results: We have genotyped a large population with type 2 diabetes (n = 1107), two populations
of non-diabetics from Glasgow (n = 186) and Dundee (n = 254) and also a healthy group undergoing
physical training (n = 148) and investigated the association of genotype with body mass index. This
analysis has demonstrated that the Ala12 and T1431 alleles are present together in approximately
70% of the carriers. By considering the other 30% of individuals with haplotypes that only carry one
of these polymorphisms, we have demonstrated that the Ala12 allele is consistently associated with
a lower BMI, whilst the T1431 allele is consistently associated with higher BMI.
Conclusion: This study has therefore revealed an opposing interaction of these polymorphisms,
which may help to explain previous inconsistencies in the association of PPARG polymorphisms and
body weight.
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Background
PPARγ plays a fundamental role in adipogenesis and insu-
lin sensitisation [1] and is a candidate gene for susceptibil-
ity to obesity and type II diabetes mellitus. A common
structural polymorphism has been detected in the PPARγ
gene consisting of a proline (Pro) to alanine (Ala) substi-
tution [2]). and is located at codon 12 (Pro12Ala) of
PPARγ2. The Ala containing variant may have reduced ac-
tivity compared to the Pro isoform [3]). This polymor-
phism has been extensively investigated for association
with obesity and type 2 diabetes mellitus [3–25]. The Ala
allele is associated with a modest protective effect against
type 2 diabetes with an odds ratio of 0.8 [4]. Increased
weight and body mass index, which themselves predis-
pose to type 2 diabetes, have however been inconsistently
associated with the Pro12Ala polymorphism with some
studies indicating that the Ala allele is associated with a
higher BMI [5,18,24,25], a lower BMI [3,8,26,27], while
other studies have found no association [11,24,28–30]. A
second polymorphism has been detected in exon 6 at nu-
cleotide 1431 of PPARG[2] resulting in a silent substitu-
tion from C to T (C1431T), this was not originally found
to be associated with BMI [31,32]. Two further studies
have, however, shown an association of the T1431 allele
with higher BMI [25,33].
The Pro12Ala and C1431T polymorphisms are in linkage
disequilibrium [18,25]). One study [25] demonstrated
that both rare alleles were associated with an increased
body weight in women, and when they occurred together
the overall effect was additive.
It is not surprising given this allelic association that phe-
notypes associated with the Pro12Ala polymorphism also
associate with the C1431T polymorphism and vice versa,
when the polymorphisms are considered in isolation.
However it is also possible that these polymorphisms dif-
ferentially mark separate haplotypes each associated with
a distinct phenotypic effect, which has not been explored
to date. In order to investigate this we examined associa-
tion of PPARG haplotypes with BMI in a large sample of
subjects with type 2 diabetes in Tayside, Scotland. We
demonstrate that increased body mass is associated with
the Pro-T haplotype, whereas the Ala-C haplotype is asso-
ciated with a lower body mass when compared to the
common  Pro-C haplotype. This finding was then con-
firmed in three subsequent independent studies. Firstly in
two non-diabetic populations from Scotland and second-
ly in a prospective group of young healthy male army re-
cruits undergoing physical training.
Results
Both polymorphisms are individually associated with an in-
creased BMI in the type 2 diabetic population
Observed Pro12Ala and C1431T genotype frequencies
and allele frequencies are given in table 1. Allele frequen-
cies did not differ significantly from Hardy-Weinberg
equilibrium. Non-significant increases in BMI were ob-
served with both polymorphisms (table 1). This was only
significant when the C1431T genotypes were collapsed
(rare allele carriers and homozygotes combined) (p =
0.027). Collapsing the Pro12Ala genotypes in a similar
manner did not achieve significance. The two polymor-
phisms were in tight linkage disequilibrium, as shown in
table 2, thus suggesting that phenotypes observed with
one polymorphism may be due to linkage with the other.
Regression analysis reveals opposing roles of the Pro12Ala 
and C1431T alleles in BMI in the type 2 diabetic popula-
tion
The effect of the variants on BMI was analysed using mul-
tiple linear regression. For heavier type 2 diabetics (BMI >
75th percentile) there was a highly significant predictive
power of the two genotypes for BMI (p = 0.008), with the
presence of the T1431 allele being associated with an in-
creased BMI (β = 2.9 kg/m2, p = 0.002) and the Ala12 al-
lele showing a trend to reduced BMI (β = -1.7 kg/m2, p =
0.072). Analysis of lighter individuals showed very little
relationship between body weight and genotype
Weight is modulated in an opposing fashion by haplotypes 
of Pro12Ala and C1431T
As the regression analysis indicated opposing associations
of each polymorphism with BMI and their linkage dise-
quilibrium meant that their interaction could not be ana-
lysed in this way, individuals were separated into groups
carrying the unequivocal haplotypes, Pro-C, Pro-T, Ala-C
and the mixed haplotype group, Ala:T. The Ala-C and the
Pro-T haplotypes allowed us to examine the role of Ala12
independently of T1431 and vice versa.
There was an association of the Pro-T haplotype with a
higher BMI compared to individuals with the Pro-C or Ala-
C haplotypes (Figure 1). As predicted by the regression
analysis, the effect of the haplotype on BMI was most no-
ticeable and achieved significance, when the heavier indi-
viduals were considered (Figure 1B, p = 0.0342, one-way
ANOVA). The data for the individuals with the mixed hap-
lotype, Ala:T, were shown in this analysis for comparison.
This group consisted of an unknown mixture of haplo-
types and the observed mean BMI tended to be intermedi-
ate, as would be predicted from the regression analysis
and the opposing nature of the polymorphisms when
present singly in the Ala-C and Pro-T haplotypes.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/21
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PPARG polymorphisms are associated with altered weight 
ranges
As the effect of genotype was dependant on the weight
range of the population, we examined the distribution of
BMI in the total population in more detail. The Pro-T dis-
played the highest coefficient of variation (Cv = 24.6%),
followed by Ala-T (Cv = 19.86%), and Pro-C (Cv =
18.87%), while the Ala-C displayed the lowest variance
(Cv= 16.5%). These difference were highly significant as
defined by Bartlett's test for equality of variance, p =
0.0004).
Associations of weight regulation and PPARG haplotype 
are replicated in a non-diabetic cohort
As the above analysis was intriguing, yet rather explorato-
ry in nature, we applied an identical statistical analysis to
two small non-diabetic cohorts for replication purposes.
Whilst the two cohorts from Dundee and Glasgow, both
had a similar range of BMI and age, they both had a lower
mean BMI than the type 2 diabetic population. In these
populations the individual polymorphisms had very little
effect on mean BMI (data not shown). However, analysis
of BMI in the combined non-diabetic population by mul-
tiple regression confirmed an opposing role for the two
polymorphisms. Again the 1431T allele was associated
with an increased BMI (β = 1.3 kg/m2, p = 0.03) and the
Ala12 with a reduced BMI (β = -1.3 kg/m2, p = 0.03). Anal-
ysis of the BMI by haplotype in the two non-diabetic co-
horts again confirmed the opposing nature of the Pro-T
and Ala-C haplotypes (Figure 2A). When we examined the
heavier individuals, with a BMI in the upper quartile, the
magnitude of the genotypic effect was increased in a sim-
Table 1: Observed PPARγ Genotype and allele frequencies and their association with BMI in the Tayside type 2 diabetic population.
Polymorphism Type 2 Diabetic BMI SD p
Pro12Ala Pro/Pro 869 30.7 6.0
Pro/Ala 227 31.2 6.9 0.3
Ala/Ala 11 32.9 6.2
Total 1107
Allele frequencies Pro 0.888 (0.874–0.901)
Ala 0.112 (0.099–0.126)
C1431T C/C 852 30.6 5.7
C/T 248 31.6 6.8 0.5*
T/T 8 32.3 3.8
Total 1107
Allele frequencies C 0.882 (0.868–0.895)
T 0.119 (0.106–0.133)
*Comparison by t test by presence or absence of the T allele p = 0.027
Table 2: Frequencies of combined PPARγ genotypes and estimated haplotypes.
Type 2 Diabetic
Genotype N % Haplotype freq. 95% CI
Pro/Pro-C/C 793 71.6 Pro-C 0.850 0.829–0.871
Pro/Pro-C/T 76 6.9
Pro/Pro-T/T 0 0 Pro-T 0.037 0.026–0.048
Pro/Ala-C/C 57 5.1
Pro/Ala-C/T 166 15.0
Pro/Ala-T/T 40 . 4
Ala/Ala-C/C 2 0.2 Ala-C 0.031 0.021–0.041
Ala/Ala-C/T 50 . 5
Ala/Ala-T/T 4 0.4 Ala-T 0.081 0.065–0.097
Total 1107 100
D' = 0.697 SD 0.031BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/21
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ilar fashion to that observed in the diabetic population
(Figure 2B, p = 0.0431, one-way ANOVA). Moreover, the
genotype/BMI variance interaction observed in the type 2
diabetic cohort was replicated very closely, with an identi-
cal rank order of haplotypes. (Pro-T = 19.87%, Ala-T =
18.25%,  Pro-C = 16.42% and Ala-C = 12.85%). Again
these differences in variance were significant (Bartlett's
test for equality of variance, p = 0.02).
Opposing associations of the PPARG haplotypes are also 
observed in exercise-induced weight change
To further confirm the opposing nature of the PPARG pol-
ymorphisms, we analysed the haplotypes in a study of
army recruits during 10 weeks intensive training [35].
There were no significant baseline BMI differences be-
tween the haplotypes (data not shown). When we exam-
ined the change in BMI observed during training, the
Pro12Ala polymorphism showed no association with
change in BMI (p = 0.57), however the T1431 allele carri-
ers showed a significantly greater increase in BMI than
C1431 allele homozygotes (CC = 0.06 kg/m2, CT+TT =
0.41 kg/m2, p = 0.05). When both polymorphisms were
Figure 1
PPARG Pro12Ala and C1431T have an opposing asso-
ciation with BMI in a type 2 diabetic population. A.
Shown are the mean BMIs of subjects with type 2 diabetes
within derived haplotype, expressed as a difference in mean
BMI from the common Pro-C haplotype. The standard error
of the mean BMI is indicated B. The individuals with a BMI in
the upper quartile of BMI (BMI > 75th centile, 33.65 kg/m2)
were analysed as above.
Figure 2
PPARG Pro12Ala and C1431T also have an opposing
association with BMI in non-diabetic populations. A.
Shown are the mean BMIs within derived haplotype
expressed as a difference in mean BMI from the common Pro-
C haplotype for the combined Glasgow and Dundee non-dia-
betic populations. The standard error of the mean BMI is
indicated. B. The individuals with a BMI in the upper quartile
of the combined population (BMI > 27.9 kg/m2) were ana-
lysed as above.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/21
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considered together we found a significant association be-
tween BMI change and the PPARγ haplotypes (Figure 3).
Regression analysis revealed a highly significant interac-
tion with the T allele and change in BMI (T1431 allele β =
0.67 kg/m2, p = 0.004, Ala12 allele β = -0.56 kg/m2, P =
0.03). Again this pattern mirrored that observed in the
other populations with a greater weight gain in the Pro-T
haplotype and a lower BMI change in the individuals with
Ala-C haplotype, compared to the common Pro-C haplo-
type.
Discussion
We have revealed robust and opposing associations of the
linked Pro12Ala and C1431T polymorphisms of the
PPARG locus with BMI by considering haplotypes. The
haplotypes individually marked by the T1431 and Ala12
alleles were found to be consistently associated with an in-
creased and decreased BMI respectively. This observation
has been confirmed in four separate populations.
Interestingly, haplotypes were associated with large differ-
ences in variance of BMI, and this appears to be a stronger
effect than was observed with the mean values. The groups
with the Pro-T haplotype had a consistently larger coeffi-
cient of variation, suggesting that the weight in Pro-T indi-
viduals is less regulated. Conversely, the Ala-C haplotype
was associated with the smallest coefficient of variation,
suggesting a much tighter control of body weight. This
data strongly supports the hypothesis that the action of
genetic variation at the PPARG locus is influenced by oth-
er genetic or environmental influences. This has been sug-
gested previously in the case of the Pro12Ala variant,
where interactions with obesity [8], diet [17], birth-weight
[38] and weight regain after dieting [39] have been ob-
served. Interaction with other genes that modulate body
weight may also occur, as demonstrated for the β3-adren-
oceptor Trp64Arg polymorphism which strongly interacts
with Pro12Ala in determining body weight [40].
Previous studies have observed differences in the effect of
the Ala12 allele in lean and obese individuals [8]. This is
in agreement with our study where we find little associa-
tion of PPARG haplotype in the BMI of lean individuals
from any of our study groups; however, we consistently
see the opposing effects of the polymorphisms in heavier
individuals. In addition, the differences in change in BMI
observed after intensive physical exercise during training
in the young army recruits, further reinforces the concept
that variation at the PPARG locus effects the regulation of
weight in the response to environmental stimuli. This is
the first study to examine such a relationship between
PPARG genotypes and exercise in the control of body
weight.
The association of genotype with BMI was the same in
both the populations with and without diabetes, demon-
strating that disease status or medication usage does not
influence this observation overall. However, this study
can not exclude the possibility that there may be interac-
tions between PPARG genotype and these parameters.
Furthermore, the diversity of potential treatments in the
diabetic population does not allow for such an analysis,
which will require a larger population. No significant dif-
ferences in age and gender by haplotype were observed in
our study, however again we cannot exclude a modulatory
role of these parameters on the relationship between BMI
and PPARG genotype.
It is also clear that the extent of allelic disequilibrium may
be different in geographically/ethnically distinct popula-
tions [41], and as such, the relationship between the
Pro12Ala and C1431T polymorphism may be different in
different ethnic groups and thus provide discordant asso-
ciations when studied in isolation. This emphasises po-
tential pitfalls in interpreting the results of association
studies when polymorphisms are considered in isolation.
The phenomenon observed in this study may represent a
common genetic feature, as opposing phenotypic associa-
tions with tightly linked SNPs have also been character-
ised at the PPARA locus [42,43].
Finally, it remains unclear whether either the C1431T or
the Pro12Ala polymorphisms have a direct functional im-
pact on the activity of PPARγ and thus in the modulation
of body weight, or whether there are further, as yet unde-
tected, functional polymorphisms linked with these hap-
lotypes.
Conclusions
Two common polymorphisms in the PPARG locus are in
close linkage disequilibrium and have opposing associa-
Figure 3
PPARG haplotype associations are replicated in army
volunteers in response to exercise. Shown is the mean
change in BMI observed during basic training by haplotype.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/21
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tion with body weight. These findings may help explain
some of the discrepancies in population studies where
only one of these polymorphisms has been studied.
Whilst the genetics of common variation at the PPARG lo-
cus appear to be complex, unravelling this complexity is
continuing to reveal that it has a role in the modulation of
body weight.
Methods
Tayside diabetic population
In Tayside, Scotland detailed clinical information on all
individuals with diabetes mellitus is recorded on an elec-
tronic clinical information system known as DARTS (Dia-
betes Audit and Research in Tayside Scotland) which has
been described elsewhere [34]. In brief, electronic record
linkage techniques have identified all people with diabe-
tes in the population of Tayside with a sensitivity of 97%.
All clinical data are recorded according to a standard data-
set and all case records are validated by a team of dedicat-
ed research nurses. All such patients are invited to
participate in the genotyping initiative. Following written
informed consent, a single sample of blood is collected for
DNA extraction and genotyping and the individual as-
signed a unique system code number for anonymisation
purposes. Full compliance with NHS data protection and
encryption standards is maintained. At the time of this
study, of the approximately 10,000 subjects registered on
DARTS, around 1300 samples had been prepared. Geno-
type information is stored together with the anonymised
clinical information on an SQL database. The population
in this study consisted of a free-living clinical population
selected only on the basis of having type 2 diabetes and at-
tending a diabetes clinic in Tayside. All subjects were of
Caucasian ethnicity.
Non-diabetic population
This consisted of 446 healthy adult Caucasian individuals
amalgamated from two separate Scottish cohorts of
healthy controls. The first consisted of 90 male and 102
female adults who had been randomly selected from the
Glasgow area. The second consisted of 186 female and 68
male adults recruited as matched controls for a breast can-
cer study. The relevant case/control comparisons will be
described elsewhere. The BMI of each individual was re-
corded once at the time of genotyping.
Army recruits
As a separate study the association of genotype with
change in weight during exercise training was investigat-
ed. This sample has been described previously [35]. Brief-
ly, 148 young healthy white male individuals underwent
an identical mixed strength and endurance-training pro-
gramme for 10 weeks and the change in BMI during the
training was determined.
Genotype determination
DNA was stored at -20°C on 96 well plates. Genotyping
for PPARγ Pro12Ala and C1431T polymorphisms was car-
ried out on the diabetic and non-diabetic populations us-
ing Taqman (Applied Biosystems) allelic discrimination
assays. Oligonucleotides used for allelic discrimination
assays were as follows:
Pro12Forward: TCCATGCTGTTATGGGTGAAACT,
Pro12Reverse: CTTTACCTTGTGATATGTTTGCAGACA,
Pro12 Probe (Fam labelled): TCTCCTATTGACCCA-
GAAAGCGATTCCTT,
Ala12 Probe (Vic labelled) TCTCCTATTGACGCA-
GAAAGCGATTCCTT,
C1431T forward: CTGTTTGCCAAGCTGCTCC,
C1431T Reverse: GAGCGGGTGAAGACTCATGTC,
C1431 Probe (Fam labelled): ATTGTCACGGAACACGT-
GCAGCTACT,
T1431 Probe (Tet labelled): ATTGTCACGGAACATGT-
GCAGCTACT
Of the 495 non-diabetic individuals 490 were genotyped
for the Pro12Ala polymorphism and 476 for the C1431T.
The army recruits were analysed by PCR/RFLP analysis as
previously described [13,31].
Unequivocal haplotypes were assigned to all genotypes
except for double heterozygotes (i.e. Pro/Ala;C/T) who as
a group have an unknown mixture of the four possible
haplotypes (Pro-C, Pro-T, Ala-C, and Ala-T). Thus the Pro/
Pro;C/C genotype is homozygous for the Pro-C haplotype,
the Pro/Pro;C/T and Pro/Pro;T/T genotypes are hetero-
zygous and homozygous respectively for the Pro-T, and
Pro/Ala; C/C and Ala/Ala;C/C genotypes heterozygous
and homozygous for the Ala-C haplotype. By combining
genotypes in this way the phenotypic associations of the
Pro-T, and Ala-C haplotypes could be compared to the
common Pro-C. Individuals with a doubly homozygous
genotype (Ala/Ala;T/T) being homozygous for the Ala-T
haplotype were too rare to be analysed.
Statistical analyses
All statistical analyses were carried out using SPSS for Win-
dows version 10 and Instat for the Macintosh version 3
(Graphpad software, San Diego, CA). Graphical represen-
tations of the data were prepared using Graphpad Prism
for the Macintosh version 3 (Graphpad software, San Di-
ego, CA). ANOVA was used to compare BMI between gen-BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/21
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otypes. Where biologically appropriate the rare allele
homozygotes were combined with the heterozygotes and
the difference in BMI with and without the allele com-
pared with Student's t test. Where distributions were not
normal the Mann-Whitney U test was employed. Allele
frequencies were compared between populations using
Chi square. Allelic associations were analysed by compar-
ing the likelihood of the data under the assumptions of no
association and of complete association using the EH pro-
gram [36]. This allowed subsequent determination of es-
timated haplotype frequencies and estimated linkage
disequilibrium coefficient, D through the use of the 2LD
program [37]. D was expressed as D', giving the value of D
as a percentage of the maximum calculated value given
the observed allele frequencies.
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